Inventor
SCHWAEBLE HANS-WILHELM
GB19 patents
⚠️ This page may combine multiple inventors who share the name “SCHWAEBLE HANS-WILHELM”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
OMEROS CORP
11 patentsUS7919094B2Apr 5, 2011
Methods for treating conditions associated with MASP-2 dependent complement activation
OMEROS CORP86 citations95
US9644035B2May 9, 2017
Methods for treating conditions associated with MASP-2 dependent complement activation
OMEROS CORP18 citations92
US10059776B2Aug 28, 2018
Methods for treating conditions associated with MASP-2 dependent complement activation
OMEROS CORP2 citations73
US10870708B2Dec 22, 2020
Methods for inhibiting angiogenesis in a subject in need thereof
OMEROS CORP3 citations71
US11896621B2Feb 13, 2024
Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant
OMEROS CORP0 citations62
US11884742B2Jan 30, 2024
Methods for treating conditions associated with MASP-2 dependent complement activation
OMEROS CORP0 citations62
US11525011B2Dec 13, 2022
Methods of inhibiting MASP-2-dependent complement activation in a subject suffering from catastrophic antiphospholipid syndrome
OMEROS CORP1 citations62
US11013772B2May 25, 2021
Methods for treating and/or preventing graft-versus-host disease and/or diffuse alveolar hemorrhage and/or veno-occlusive disease associated with hematopoietic stem cell transplant
OMEROS CORP0 citations62
US11981748B2May 14, 2024
Methods for inhibiting angiogenesis in a subject in need thereof
OMEROS CORP0 citations60
US11981749B2May 14, 2024
Methods for treating conditions associated with MASP-2 dependent complement activation
OMEROS CORP1 citations57
US10202465B2Feb 12, 2019
Methods for treating conditions associated with MASP-2 dependent complement activation
OMEROS CORP0 citations52
UNIV LEICESTER
4 patentsUS10736960B2Aug 11, 2020
Methods for inhibiting fibrosis in a subject in need thereof
UNIV LEICESTER3 citations65
US12005117B2Jun 11, 2024
Methods for inhibiting fibrosis in a subject in need thereof
UNIV LEICESTER0 citations56
US10660317B2May 26, 2020
Genetically modified non-human mammals and cells
UNIV LEICESTER0 citations49
US10626184B2Apr 21, 2020
Monoclonal antibodies, compositions and methods for detecting mucin-like protein (MLP) as a biomarker for ovarian and pancreatic cancer
UNIV LEICESTER0 citations41
SCHWAEBLE HANS-WILHELM
2 patentsUS8652477B2Feb 18, 2014
Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation
SCHWAEBLE HANS-WILHELM61 citations95
US8840893B2Sep 23, 2014
Methods for treating conditions associated with MASP-2 dependent complement activation
SCHWAEBLE HANS-WILHELM36 citations92